NCT04888741
Methods of T Cell Depletion Trial (MoTD)
Recruiting · Phase 2 · University of Birmingham · registry updated 2026-05-05
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
Inclusion
- Availability of suitably matched unrelated donor (9/10 or 10/10)
- Planned to receive one of the following RIC protocols:
- Fludarabine-Melphalan (Fludarabine 120-180mg/m2 IV; melphalan ≤ 150mg/m2 IV)
- BEAM or LEAM (carmustine 300mg/m2 IV or lomustine 200mg/m2 IV with: etoposide 800 mg/m2 IV; cytarabine 1600mg/m2 IV; melphalan 140mg/m2 IV)
- Fludarabine-Busulphan (Fludarabine 120-180mg/m2 IV; Busulphan ≤ 8mg/kg PO or 6.4mg/kg IV)
- Fludarabine- Treosulfan (Fludarabine 150mg/m2 IV; Treosulfan 30g/m2 IV)
Exclusion
- Use of any method of graft manipulation (excluding storage of future DLI)
- Use of alemtuzumab or any method of T cell depletion except those that are protocol-defined
- Known hypersensitivity to study drugs or history of hypersensitivity to rabbits
- Pregnant or lactating women
- Adults of reproductive potential not willing to use appropriate, highly effective, contraception during the specified period
- Life expectancy \<8 weeks